ARWR Arrowhead Pharmaceuticals - plozasiran achieves 79% and 81% median triglyceride reduction in shasta-3 and shasta-4 - Plozasiran shows s
ARWR Arrowhead Pharmaceuticals - plozasiran achieves 79% and 81% median triglyceride reduction in shasta-3 and shasta-4 - Plozasiran shows significant reduction in acute pancreatitis events, 100% in high-risk patients - Plozasiran demonstrates consistent safety profile with no new safety signals - To file supplemental NDA for plozasiran with U.S. FDA before end of 2026
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.